{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:46:15Z","timestamp":1790423175177,"version":"4.1.0"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Intranasal delivery provides a rapid, non-invasive route to the central nervous system, bypassing the blood\u2013brain barrier and first-pass metabolism. However, its therapeutic potential remains constrained by the nasal cavity\u2019s complex anatomy, the restricted surface area and permeability of the olfactory epithelium, and short drug residence times. Recent advances in nanotechnology and synthetic biology have enabled the development of autonomous and programmable delivery systems that can target the olfactory epithelium, enhance brain entry and sustain therapeutic release. This review highlights current strategies for engineering intranasal drug delivery vectors that can replicate or extend cellular functions to enable autonomous nose-to-brain drug delivery. These vectors include: synthetic nanoparticles that mimic essential cellular activities and allow for modular surface modification; extracellular vesicles that naturally carry therapeutic cargo and exhibit parent-cell-derived tropism; and living therapeutics, such as engineered microbes, viruses or stem cells, that respond dynamically to host environments and can be genetically programmed for precise payload production. Emphasis is placed on the modular design of functional components, host-responsive interactions tailored to anatomical and physiological cues, and the integration of programmable functions that collectively drive delivery autonomy and therapeutic efficacy. Together, these advances position intranasal delivery as a versatile platform for treating neurological disorders, offering a foundation for future translational development.<\/jats:p>","DOI":"10.1038\/s12276-026-01781-5","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:02:18Z","timestamp":1785715338000},"page":"2417-2429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Autonomous intranasal delivery systems for central nervous system therapeutics"],"prefix":"10.1038","volume":"58","author":[{"given":"Haosheng","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh Kumar","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6448-6319","authenticated-orcid":false,"given":"Matthew Wook","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"1781_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-022-00937-4","volume":"15","author":"HK Alajangi","year":"2022","unstructured":"Alajangi, H. K. et al. Blood-brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders. Mol. Brain 15, 49 (2022).","journal-title":"Mol. Brain"},{"key":"1781_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1341295","volume":"15","author":"Q Huang","year":"2024","unstructured":"Huang, Q., Chen, X., Yu, S., Gong, G. & Shu, H. Research progress in brain-targeted nasal drug delivery. Front. Aging Neurosci. 15, 1341295 (2024).","journal-title":"Front. Aging Neurosci."},{"key":"1781_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-9-S3-S5","volume":"9","author":"LR Hanson","year":"2008","unstructured":"Hanson, L. R. & Frey, W. H. 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 9, S5 (2008).","journal-title":"BMC Neurosci."},{"key":"1781_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104558","volume":"91","author":"I Spera","year":"2023","unstructured":"Spera, I. et al. Open pathways for cerebrospinal fluid outflow at the cribriform plate along the olfactory nerves. EBioMedicine 91, 104558 (2023).","journal-title":"EBioMedicine"},{"key":"1781_CR5","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.44278","author":"JN Norwood","year":"2019","unstructured":"Norwood, J. N. et al. Anatomical basis and physiological role of cerebrospinal fluid transport through the murine cribriform plate. Elife https:\/\/doi.org\/10.7554\/eLife.44278 (2019).","journal-title":"Elife"},{"key":"1781_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","volume":"127","author":"RG Thorne","year":"2004","unstructured":"Thorne, R. G., Pronk, G. J., Padmanabhan, V. & Frey, W. H. 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481\u2013496 (2004).","journal-title":"Neuroscience"},{"key":"1781_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","volume":"195","author":"TP Crowe","year":"2018","unstructured":"Crowe, T. P., Greenlee, M. H. W., Kanthasamy, A. G. & Hsu, W. H. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 195, 44\u201352 (2018).","journal-title":"Life Sci."},{"key":"1781_CR8","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"JJ Lochhead","year":"2012","unstructured":"Lochhead, J. J. & Thorne, R. G. Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev. 64, 614\u2013628 (2012).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1781_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11080367","author":"S Ladel","year":"2019","unstructured":"Ladel, S. et al. Improved in vitro model for intranasal mucosal drug delivery: primary olfactory and respiratory epithelial cells compared with the permanent nasal cell line RPMI 2650. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics11080367 (2019).","journal-title":"Pharmaceutics"},{"key":"1781_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.842592","volume":"13","author":"TD Rogers","year":"2022","unstructured":"Rogers, T. D. et al. Regional differences in mucociliary clearance in the upper and lower airways. Front. Physiol. 13, 842592 (2022).","journal-title":"Front. Physiol."},{"key":"1781_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0169-409X(97)00059-8","volume":"29","author":"E Marttin","year":"1998","unstructured":"Marttin, E., Schipper, N. G. M., Verhoef, J. C. & Merkus, F. W. H. M. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv. Drug Deliv. Rev. 29, 13\u201338 (1998).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1781_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/01926230600713475","volume":"34","author":"JR Harkema","year":"2006","unstructured":"Harkema, J. R., Carey, S. A. & Wagner, J. G. The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol. Pathol. 34, 252\u2013269 (2006).","journal-title":"Toxicol. Pathol."},{"key":"1781_CR13","doi-asserted-by":"publisher","first-page":"566","DOI":"10.2174\/156720112803529828","volume":"9","author":"S Gizurarson","year":"2012","unstructured":"Gizurarson, S. Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr. Drug Deliv. 9, 566\u2013582 (2012).","journal-title":"Curr. Drug Deliv."},{"key":"1781_CR14","unstructured":"Pandey, V. et al. Drug delivery systems. (Elsevier,2020)."},{"key":"1781_CR15","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/jps.21924","volume":"99","author":"SV Dhuria","year":"2010","unstructured":"Dhuria, S. V., Hanson, L. R. & Frey, W. H. 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 99, 1654\u20131673 (2010).","journal-title":"J. Pharm. Sci."},{"key":"1781_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","volume":"12","author":"LA Keller","year":"2022","unstructured":"Keller, L. A., Merkel, O. & Popp, A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug. Deliv. Transl. Res. 12, 735\u2013757 (2022).","journal-title":"Drug. Deliv. Transl. Res."},{"key":"1781_CR17","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1007\/s13346-021-01086-2","volume":"12","author":"ML Borrajo","year":"2022","unstructured":"Borrajo, M. L. & Alonso, M. J. Using nanotechnology to deliver biomolecules from nose to brain \u2014 peptides, proteins, monoclonal antibodies and RNA. Drug Deliv. Transl. Res. 12, 862\u2013880 (2022).","journal-title":"Drug Deliv. Transl. Res."},{"key":"1781_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0378-5173(01)00602-0","volume":"217","author":"RJ Soane","year":"2001","unstructured":"Soane, R. J., Hinchcliffe, M., Davis, S. S. & Illum, L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int. J. Pharm. 217, 183\u2013191 (2001).","journal-title":"Int. J. Pharm."},{"key":"1781_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0378-5173(98)00367-6","volume":"178","author":"RJ Soane","year":"1999","unstructured":"Soane, R. J. et al. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int. J. Pharm. 178, 55\u201365 (1999).","journal-title":"Int. J. Pharm."},{"key":"1781_CR20","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jconrel.2020.12.050","volume":"330","author":"MJ Majcher","year":"2021","unstructured":"Majcher, M. J. et al. In situ-gelling starch nanoparticle (SNP)\/O-carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide. J. Control Release 330, 738\u2013752 (2021).","journal-title":"J. Control Release"},{"key":"1781_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108832","volume":"201","author":"CT Uppuluri","year":"2021","unstructured":"Uppuluri, C. T., Ravi, P. R. & Dalvi, A. V. Design and evaluation of thermo-responsive nasal in situ gelling system dispersed with piribedil loaded lecithin-chitosan hybrid nanoparticles for improved brain availability. Neuropharmacology 201, 108832 (2021).","journal-title":"Neuropharmacology"},{"key":"1781_CR22","doi-asserted-by":"crossref","unstructured":"Yadav, M., Kaushik, B., Rao, G. K., Srivastava, C. M. & Vaya, D. Advances and challenges in the use of chitosan and its derivatives in biomedical fields: a review. Carbohydr. Polym. Technol. Appl. 5, 100323 (2023).","DOI":"10.1016\/j.carpta.2023.100323"},{"key":"1781_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.xphs.2020.09.026","volume":"110","author":"L Wright","year":"2021","unstructured":"Wright, L. et al. A comparison of chitosan, mesoporous silica and poly(lactic-co-glycolic) acid nanocarriers for optimising intestinal uptake of oral protein therapeutics. J. Pharm. Sci.110, 217\u2013227 (2021).","journal-title":"J. Pharm. Sci."},{"key":"1781_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jddst.2019.01.011","volume":"50","author":"H Kamali","year":"2019","unstructured":"Kamali, H. et al. Comparison of in-situ forming composite using PLGA-PEG-PLGA with in-situ forming implant using PLGA: In-vitro, ex-vivo, and in-vivo evaluation of naltrexone release. J. Drug Deliv. Sci. Technol. 50, 188\u2013200 (2019).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"1781_CR25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ijbiomac.2022.08.210","volume":"221","author":"S Ahmad","year":"2022","unstructured":"Ahmad, S. et al. Brain targeted delivery of carmustine using chitosan coated nanoparticles via nasal route for glioblastoma treatment. Int. J. Biol. Macromol. 221, 435\u2013445 (2022).","journal-title":"Int. J. Biol. Macromol."},{"key":"1781_CR26","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/10837450.2020.1740257","volume":"25","author":"S Arisoy","year":"2020","unstructured":"Arisoy, S. et al. In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery. Pharm. Dev. Technol. 25, 735\u2013747 (2020).","journal-title":"Pharm. Dev. Technol."},{"key":"1781_CR27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.nano.2018.10.013","volume":"18","author":"R Li","year":"2019","unstructured":"Li, R. et al. Targeted delivery of intranasally administered nanoparticles-mediated neuroprotective peptide NR2B9c to brain and neuron for treatment of ischemic stroke. Nanomedicine 18, 380\u2013390 (2019).","journal-title":"Nanomedicine"},{"key":"1781_CR28","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.2147\/IJN.S120939","volume":"11","author":"C Bi","year":"2016","unstructured":"Bi, C. et al. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson\u2019s disease treatment. Int. J. Nanomedicine 11, 6547\u20136559 (2016).","journal-title":"Int. J. Nanomedicine"},{"key":"1781_CR29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/IJN.S151474","volume":"13","author":"Q Meng","year":"2018","unstructured":"Meng, Q. et al. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer\u2019s disease. Int. J. Nanomedicine 13, 705\u2013718 (2018).","journal-title":"Int. J. Nanomedicine"},{"key":"1781_CR30","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1021\/acsnano.7b08172","volume":"12","author":"L You","year":"2018","unstructured":"You, L. et al. Targeted brain delivery of rabies virus glycoprotein 29-modified deferoxamine-loaded nanoparticles reverses functional deficits in Parkinsonian mice. ACS Nano 12, 4123\u20134139 (2018).","journal-title":"ACS Nano"},{"key":"1781_CR31","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1080\/10717544.2018.1494226","volume":"25","author":"L Chu","year":"2018","unstructured":"Chu, L. et al. Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. Drug Deliv. 25, 1634\u20131641 (2018).","journal-title":"Drug Deliv."},{"key":"1781_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.965789","volume":"13","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. Temozolomide hexadecyl ester targeted plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration. Front. Pharmacol. 13, 965789 (2022).","journal-title":"Front. Pharmacol."},{"key":"1781_CR33","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1021\/acs.molpharmaceut.0c00170","volume":"17","author":"HK Dhaliwal","year":"2020","unstructured":"Dhaliwal, H. K., Fan, Y., Kim, J. & Amiji, M. M. Intranasal delivery and transfection of mRNA therapeutics in the brain using cationic liposomes. Mol. Pharm. 17, 1996\u20132005 (2020).","journal-title":"Mol. Pharm."},{"key":"1781_CR34","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-021-02072-0","volume":"22","author":"R Saka","year":"2021","unstructured":"Saka, R., Chella, N. & Khan, W. Development of imatinib mesylate-loaded liposomes for nose to brain delivery: in vitro and in vivo evaluation. AAPS PharmSciTech 22, 192 (2021).","journal-title":"AAPS PharmSciTech"},{"key":"1781_CR35","doi-asserted-by":"crossref","unstructured":"Vasilieva, E. A. et al. Design of glycol chitosan-decorated liposomes for the intranasal delivery of hydrophilic substances: physicochemical and in vitro\/in vivo biological assessment. Colloids Surf. A Physicochem. Eng. Asp. 693, 134073 (2024).","DOI":"10.1016\/j.colsurfa.2024.134073"},{"key":"1781_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jconrel.2022.03.017","volume":"344","author":"T Kurano","year":"2022","unstructured":"Kurano, T. et al. Nose-to-brain\/spinal cord delivery kinetics of liposomes with different surface properties. J. Controlled Release 344, 225\u2013234 (2022).","journal-title":"J. Controlled Release"},{"key":"1781_CR37","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1080\/10717544.2017.1309476","volume":"24","author":"S Nageeb El-Helaly","year":"2017","unstructured":"Nageeb El-Helaly, S., Abd Elbary, A., Kassem, M. A. & El-Nabarawi, M. A. Electrosteric stealth rivastigmine loaded liposomes for brain targeting: preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies. Drug Deliv 24, 692\u2013700 (2017).","journal-title":"Drug Deliv"},{"key":"1781_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0009-3084(93)90053-6","volume":"64","author":"M Grit","year":"1993","unstructured":"Grit, M. & Crommelin, D. J. A. Chemical stability of liposomes: implications for their physical stability. Chem. Phys. Lipids 64, 3\u201318 (1993).","journal-title":"Chem. Phys. Lipids"},{"key":"1781_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2025.114597","volume":"251","author":"J Cunha","year":"2025","unstructured":"Cunha, J. et al. Core-shell hybrid liposomes: transforming imaging diagnostics and therapeutic strategies. Colloids Surf. B Biointerfaces 251, 114597 (2025).","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"1781_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104709","volume":"86","author":"M Akanda","year":"2023","unstructured":"Akanda, M., Mithu, M. D. S. H. & Douroumis, D. Solid lipid nanoparticles: an effective lipid-based technology for cancer treatment. J. Drug Deliv. Sci. Technol. 86, 104709 (2023).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"1781_CR41","volume":"16","author":"M Navaneetha Krishnan","year":"2024","unstructured":"Navaneetha Krishnan, M., Sangeetha, S., Sree Ranjani, P. & Narayanasamy, D. The science of solid lipid nanoparticles: from fundamentals to applications. Cureus 16, e68807 (2024).","journal-title":"Cureus"},{"key":"1781_CR42","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4103\/1735-5362.235156","volume":"13","author":"P Ghasemiyeh","year":"2018","unstructured":"Ghasemiyeh, P. & Mohammadi-Samani, S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res. Pharm. Sci. 13, 288\u2013303 (2018).","journal-title":"Res. Pharm. Sci."},{"key":"1781_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2022.112863","volume":"220","author":"T Moraes-Lacerda","year":"2022","unstructured":"Moraes-Lacerda, T. & de Jesus, M. B. Mechanisms of solid lipid nanoparticles-triggered signaling pathways in eukaryotic cells. Colloids Surf. B Biointerfaces 220, 112863 (2022).","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"1781_CR44","doi-asserted-by":"publisher","first-page":"5929","DOI":"10.1021\/acsami.6b00821","volume":"8","author":"G-H Chai","year":"2016","unstructured":"Chai, G.-H. et al. Transport mechanisms of solid lipid nanoparticles across Caco-2 cell monolayers and their related cytotoxicology. ACS Appl. Mater. Interfaces 8, 5929\u20135940 (2016).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"1781_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102164","volume":"61","author":"M Yasir","year":"2021","unstructured":"Yasir, M. et al. Buspirone loaded solid lipid nanoparticles for amplification of nose to brain efficacy: formulation development, optimization by Box-Behnken design, in-vitro characterization and in-vivo biological evaluation. J. Drug Deliv. Sci. Technol. 61, 102164 (2021).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"1781_CR46","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2147\/DDDT.S102500","volume":"11","author":"AM Fatouh","year":"2017","unstructured":"Fatouh, A. M., Elshafeey, A. H. & Abdelbary, A. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics. Drug Des. Devel. Ther. 11, 1815\u20131825 (2017).","journal-title":"Drug Des. Devel. Ther."},{"key":"1781_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102377","volume":"63","author":"JB Prajapati","year":"2021","unstructured":"Prajapati, J. B. & Patel, G. C. Nose to brain delivery of rotigotine loaded solid lipid nanoparticles: quality by design based optimization and characterization. J. Drug Deliv. Sci. Technol. 63, 102377 (2021).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"1781_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120881","volume":"606","author":"CT Uppuluri","year":"2021","unstructured":"Uppuluri, C. T., Ravi, P. R. & Dalvi, A. V. Design, optimization and pharmacokinetic evaluation of piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson\u2019s disease. Int. J. Pharm. 606, 120881 (2021).","journal-title":"Int. J. Pharm."},{"key":"1781_CR49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2012.09.021","volume":"64","author":"W Mehnert","year":"2012","unstructured":"Mehnert, W. & M\u00e4der, K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 64, 83\u2013101 (2012).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1781_CR50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0378-5173(02)00180-1","volume":"242","author":"RH M\u00fcller","year":"2002","unstructured":"M\u00fcller, R. H., Radtke, M. & Wissing, S. A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 242, 121\u2013128 (2002).","journal-title":"Int. J. Pharm."},{"key":"1781_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","volume":"12","author":"A Beloqui","year":"2016","unstructured":"Beloqui, A., Solin\u00eds, M. \u00c1, Rodr\u00edguez-Gasc\u00f3n, A., Almeida, A. J. & Pr\u00e9at, V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine 12, 143\u2013161 (2016).","journal-title":"Nanomedicine"},{"key":"1781_CR52","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2147\/IJN.S402447","volume":"18","author":"MK Shehata","year":"2023","unstructured":"Shehata, M. K., Ismail, A. A. & Kamel, M. A. Nose to brain delivery of astaxanthin-loaded nanostructured lipid carriers in rat model of Alzheimer\u2019s disease: preparation, in vitro and in vivo evaluation. Int. J. Nanomedicine 18, 1631\u20131658 (2023).","journal-title":"Int. J. Nanomedicine"},{"key":"1781_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102533","volume":"64","author":"HP Patel","year":"2021","unstructured":"Patel, H. P. et al. Clozapine loaded nanostructured lipid carriers engineered for brain targeting via nose-to-brain delivery: optimization and in vivo pharmacokinetic studies. J. Drug Deliv. Sci. Technol. 64, 102533 (2021).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"1781_CR54","volume":"5","author":"E Taha","year":"2023","unstructured":"Taha, E. et al. Cod liver oil nano-structured lipid carriers (Cod-NLCs) as a promising platform for nose to brain delivery: preparation, in vitro optimization, ex vivo cytotoxicity & in vivo biodistribution utilizing radioiodinated zopiclone. Int. J. Pharm. X 5, 100160 (2023).","journal-title":"Int. J. Pharm. X"},{"key":"1781_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122232","volume":"627","author":"A Zafar","year":"2022","unstructured":"Zafar, A. et al. Formulation of intranasal surface engineered nanostructured lipid carriers of rotigotine: full factorial design optimization, in vitro characterization, and pharmacokinetic evaluation. Int. J. Pharm. 627, 122232 (2022).","journal-title":"Int. J. Pharm."},{"key":"1781_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101640","author":"SC Nair","year":"2021","unstructured":"Nair, S. C., Vinayan, K. P. & Mangalathillam, S. Nose to brain delivery of phenytoin sodium loaded nano lipid carriers: formulation, drug release, permeation and in vivo pharmacokinetic studies. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics13101640 (2021).","journal-title":"Pharmaceutics"},{"key":"1781_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.751321","volume":"12","author":"S Silva","year":"2021","unstructured":"Silva, S. et al. Encapsulated escitalopram and paroxetine intranasal co-administration: in vitro\/in vivo evaluation. Front. Pharmacol. 12, 751321 (2021).","journal-title":"Front. Pharmacol."},{"key":"1781_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030656","author":"FF Qizilbash","year":"2022","unstructured":"Qizilbash, F. F. et al. Thymoquinone-enriched naringenin-loaded nanostructured lipid carrier for brain delivery via nasal route: in vitro prospect and in vivo therapeutic efficacy for the treatment of depression. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics14030656 (2022).","journal-title":"Pharmaceutics"},{"key":"1781_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102939","volume":"67","author":"KM Noorulla","year":"2022","unstructured":"Noorulla, K. M. et al. Intranasal delivery of chitosan decorated nanostructured lipid carriers of buspirone for brain targeting: formulation development, optimization and in-vivo preclinical evaluation. J. Drug Deliv. Sci. Technol. 67, 102939 (2022).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"1781_CR60","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12668-020-00821-2","volume":"11","author":"D Tripathi","year":"2021","unstructured":"Tripathi, D. et al. Augmented brain delivery of cinnarizine through nanostructured lipid carriers loaded in situ gel: in vitro and pharmacokinetic evaluation. BioNanoScience 11, 159\u2013171 (2021).","journal-title":"BioNanoScience"},{"key":"1781_CR61","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1089\/adt.2022.044","volume":"20","author":"D Mathure","year":"2022","unstructured":"Mathure, D., Ranpise, H., Awasthi, R. & Pawar, A. Formulation and characterization of nanostructured lipid carriers of rizatriptan benzoate-loaded in situ nasal gel for brain targeting. Assay Drug. Dev. Technol. 20, 211\u2013224 (2022).","journal-title":"Assay Drug. Dev. Technol."},{"key":"1781_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041254","author":"TS Koduru","year":"2023","unstructured":"Koduru, T. S., Gupta, V. N. & Seetjaraman, S. A dual therapy of nanostructured lipid carrier loaded with teriflunomide-A dihydro-orotate dehydrogenase inhibitor and an miR-155-antagomir in cuprizone-induced C57BL\/6J mouse. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics15041254 (2023).","journal-title":"Pharmaceutics"},{"key":"1781_CR63","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/03639045.2019.1576724","volume":"45","author":"DG Gadhave","year":"2019","unstructured":"Gadhave, D. G. & Kokare, C. R. Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies. Drug Dev. Ind. Pharm. 45, 839\u2013851 (2019).","journal-title":"Drug Dev. Ind. Pharm."},{"key":"1781_CR64","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40199-019-00304-0","volume":"27","author":"S Palagati","year":"2019","unstructured":"Palagati, S., Sv, S. & Kesavan, B. R. Application of computational tools for the designing of oleuropein loaded nanostructured lipid carrier for brain targeting through nasal route. Daru 27, 695\u2013708 (2019).","journal-title":"Daru"},{"key":"1781_CR65","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ejpb.2016.08.001","volume":"108","author":"S Doktorovov\u00e1","year":"2016","unstructured":"Doktorovov\u00e1, S., Kova\u010devi\u0107, A. B., Garcia, M. L. & Souto, E. B. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: current evidence from in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 108, 235\u2013252 (2016).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"1781_CR66","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ijpharm.2014.07.025","volume":"473","author":"YM Gabal","year":"2014","unstructured":"Gabal, Y. M., Kamel, A. O., Sammour, O. A. & Elshafeey, A. H. Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route. Int. J. Pharm. 473, 442\u2013457 (2014).","journal-title":"Int. J. Pharm."},{"key":"1781_CR67","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","volume":"3","author":"M Mehta","year":"2023","unstructured":"Mehta, M. et al. Lipid-based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development. ACS Mater. Au. 3, 600\u2013619 (2023).","journal-title":"ACS Mater. Au."},{"key":"1781_CR68","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.omtn.2018.09.019","volume":"13","author":"G Hu","year":"2018","unstructured":"Hu, G. et al. Astrocyte EV-induced lincRNA-Cox2 regulates microglial phagocytosis: implications for morphine-mediated neurodegeneration. Mol. Ther. Nucl. Acids 13, 450\u2013463 (2018).","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"1781_CR69","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.7150\/thno.70951","volume":"12","author":"D Peng","year":"2022","unstructured":"Peng, D. et al. Extracellular vesicles derived from astrocyte-treated with haFGF(14-154) attenuate Alzheimer phenotype in AD mice. Theranostics 12, 3862\u20133881 (2022).","journal-title":"Theranostics"},{"key":"1781_CR70","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317402121","volume":"121","author":"ES Arvanitaki","year":"2024","unstructured":"Arvanitaki, E. S. et al. Microglia-derived extracellular vesicles trigger age-related neurodegeneration upon DNA damage. Proc. Natl Acad. Sci. 121, e2317402121 (2024).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1781_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03127-z","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Macrophage-derived extracellular vesicles: diverse mediators of pathology and therapeutics in multiple diseases. Cell Death Dis. 11, 924 (2020).","journal-title":"Cell Death Dis."},{"key":"1781_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.785728","volume":"12","author":"Y Xing","year":"2021","unstructured":"Xing, Y. et al. The immuno-modulation effect of macrophage-derived extracellular vesicles in chronic inflammatory diseases. Front. Immunol. 12, 785728 (2021).","journal-title":"Front. Immunol."},{"key":"1781_CR73","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1007\/s12640-021-00390-6","volume":"39","author":"SH Hayes","year":"2021","unstructured":"Hayes, S. H. et al. Brain targeting and toxicological assessment of the extracellular vesicle-packaged antioxidant catalase-SKL following intranasal administration in mice. Neurotox. Res. 39, 1418\u20131429 (2021).","journal-title":"Neurotox. Res."},{"key":"1781_CR74","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jconrel.2015.03.033","volume":"207","author":"MJ Haney","year":"2015","unstructured":"Haney, M. J. et al. Exosomes as drug delivery vehicles for Parkinson\u2019s disease therapy. J. Controlled Release 207, 18\u201330 (2015).","journal-title":"J. Controlled Release"},{"key":"1781_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/cells11121933","volume":"11","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y. et al. Using extracellular vesicles released by GDNF-transfected macrophages for therapy of Parkinson disease. Cells 11, 1933 (2022).","journal-title":"Cells"},{"key":"1781_CR76","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1089\/scd.2009.0418","volume":"19","author":"Z Tu","year":"2010","unstructured":"Tu, Z., Li, Q., Bu, H. & Lin, F. Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev. 19, 1803\u20131809 (2010).","journal-title":"Stem Cells Dev."},{"key":"1781_CR77","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1093\/cvr\/cvu091.37","volume":"103","author":"D Kavanagh","year":"2014","unstructured":"Kavanagh, D. et al. P351 Pretreatment of mesenchymal stem cells does not enhance their recruitment to injured tissue in a model of ischemia-reperfusion injury yet abolishes their anti-inflammatory capabilities. Cardiovasc. Res. 103, S64\u2013S64 (2014).","journal-title":"Cardiovasc. Res."},{"key":"1781_CR78","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10517-021-05109-3","volume":"170","author":"DY Zhdanova","year":"2021","unstructured":"Zhdanova, D. Y., Poltavtseva, R. A., Svirshchevskaya, E. V. & Bobkova, N. V. Effect of intranasal administration of multipotent mesenchymal stromal cell exosomes on memory of mice in Alzheimer\u2019s disease model. Bull. Exp. Biol. Med. 170, 575\u2013582 (2021).","journal-title":"Bull. Exp. Biol. Med."},{"key":"1781_CR79","doi-asserted-by":"publisher","first-page":"8129","DOI":"10.7150\/thno.62069","volume":"11","author":"AS Cone","year":"2021","unstructured":"Cone, A. S. et al. Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer\u2019s disease-like phenotypes in a preclinical mouse model. Theranostics 11, 8129\u20138142 (2021).","journal-title":"Theranostics"},{"key":"1781_CR80","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/sctm.19-0327","volume":"9","author":"M Losurdo","year":"2020","unstructured":"Losurdo, M. et al. Intranasal delivery of mesenchymal stem cell-derived extracellular vesicles exerts immunomodulatory and neuroprotective effects in a 3xTg model of Alzheimer\u2019s disease. Stem Cells Transl. Med. 9, 1068\u20131084 (2020).","journal-title":"Stem Cells Transl. Med."},{"key":"1781_CR81","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/sctm.18-0162","volume":"8","author":"K Narbute","year":"2019","unstructured":"Narbute, K. et al. Intranasal administration of extracellular vesicles derived from human teeth stem cells improves motor symptoms and normalizes tyrosine hydroxylase expression in the substantia nigra and striatum of the 6-hydroxydopamine-treated rats. Stem Cells Transl. Med. 8, 490\u2013499 (2019).","journal-title":"Stem Cells Transl. Med."},{"key":"1781_CR82","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10571-020-00865-8","volume":"41","author":"K Narbute","year":"2021","unstructured":"Narbute, K. et al. Time-dependent memory and gait improvement by intranasally-administered extracellular vesicles in Parkinson\u2019s disease model rats. Cell. Mol. Neurobiol. 41, 605\u2013613 (2021).","journal-title":"Cell. Mol. Neurobiol."},{"key":"1781_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-020-00366-x","volume":"11","author":"N Perets","year":"2020","unstructured":"Perets, N., Oron, O., Herman, S., Elliott, E. & Offen, D. Exosomes derived from mesenchymal stem cells improved core symptoms of genetically modified mouse model of autism Shank3B. Mol. Autism 11, 65 (2020).","journal-title":"Mol. Autism"},{"key":"1781_CR84","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1021\/acsabm.0c00831","volume":"3","author":"Y Liang","year":"2020","unstructured":"Liang, Y. et al. Mesenchymal stem cell-derived exosomes for treatment of autism spectrum disorder. ACS Appl. Bio Mater. 3, 6384\u20136393 (2020).","journal-title":"ACS Appl. Bio Mater."},{"key":"1781_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-018-0240-6","volume":"9","author":"N Perets","year":"2018","unstructured":"Perets, N., Hertz, S., London, M. & Offen, D. Intranasal administration of exosomes derived from mesenchymal stem cells ameliorates autistic-like behaviors of BTBR mice. Mol. Autism 9, 57 (2018).","journal-title":"Mol. Autism"},{"key":"1781_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-019-1207-z","volume":"10","author":"G Thomi","year":"2019","unstructured":"Thomi, G., Surbek, D., Haesler, V., Joerger-Messerli, M. & Schoeberlein, A. Exosomes derived from umbilical cord mesenchymal stem cells reduce microglia-mediated neuroinflammation in perinatal brain injury. Stem Cell Res. Ther. 10, 105 (2019).","journal-title":"Stem Cell Res. Ther."},{"key":"1781_CR87","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s13311-021-01076-9","volume":"18","author":"P Pathipati","year":"2021","unstructured":"Pathipati, P. et al. Mesenchymal stem cell (MSC)-derived extracellular vesicles protect from neonatal stroke by interacting with microglial cells. Neurotherapeutics 18, 1939\u20131952 (2021).","journal-title":"Neurotherapeutics"},{"key":"1781_CR88","doi-asserted-by":"publisher","first-page":"10015","DOI":"10.1021\/acsnano.9b01892","volume":"13","author":"S Guo","year":"2019","unstructured":"Guo, S. et al. Intranasal delivery of mesenchymal stem cell derived exosomes loaded with phosphatase and tensin homolog siRNA repairs complete spinal cord injury. ACS Nano 13, 10015\u201310028 (2019).","journal-title":"ACS Nano"},{"key":"1781_CR89","doi-asserted-by":"publisher","first-page":"E3536","DOI":"10.1073\/pnas.1703920114","volume":"114","author":"Q Long","year":"2017","unstructured":"Long, Q. et al. Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus. Proc. Natl Acad. Sci. 114, E3536\u2013E3545 (2017).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1781_CR90","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1634\/stemcells.2005-0342","volume":"24","author":"S Kern","year":"2006","unstructured":"Kern, S., Eichler, H., Stoeve, J., Kl\u00fcter, H. & Bieback, K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24, 1294\u20131301 (2006).","journal-title":"Stem Cells"},{"key":"1781_CR91","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1089\/107632701300062859","volume":"7","author":"PA Zuk","year":"2001","unstructured":"Zuk, P. A. et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 7, 211\u2013228 (2001).","journal-title":"Tissue Eng."},{"key":"1781_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-021-00471-7","volume":"7","author":"M Garcia-Contreras","year":"2021","unstructured":"Garcia-Contreras, M. & Thakor, A. S. Human adipose tissue-derived mesenchymal stem cells and their extracellular vesicles modulate lipopolysaccharide activated human microglia. Cell Death Discov. 7, 98 (2021).","journal-title":"Cell Death Discov."},{"key":"1781_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116424","volume":"173","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Compounding engineered mesenchymal stem cell-derived exosomes: a potential rescue strategy for retinal degeneration. Biomed. Pharmacother. 173, 116424 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"1781_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312860","author":"F Rohden","year":"2021","unstructured":"Rohden, F. et al. Functional recovery caused by human adipose tissue mesenchymal stem cell-derived extracellular vesicles administered 24 h after stroke in rats. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms222312860 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1781_CR95","volume":"22","author":"Y Geffen","year":"2020","unstructured":"Geffen, Y. et al. Exosomes derived from adipose mesenchymal stem cells: a potential non-invasive intranasal treatment for autism. Cytotherapy 22, S49 (2020).","journal-title":"Cytotherapy"},{"key":"1781_CR96","doi-asserted-by":"crossref","unstructured":"Romine, J., Gao, X. & Chen, J. Controlled cortical impact model for traumatic brain injury y. J. Vis. Exp. 51781, (2014).","DOI":"10.3791\/51781-v"},{"key":"1781_CR97","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.yexcr.2015.12.009","volume":"340","author":"R Bonafede","year":"2016","unstructured":"Bonafede, R. et al. Exosome derived from murine adipose-derived stromal cells: neuroprotective effect on in vitro model of amyotrophic lateral sclerosis. Exp. Cell Res. 340, 150\u2013158 (2016).","journal-title":"Exp. Cell Res."},{"key":"1781_CR98","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.1038\/s44319-024-00321-4","volume":"25","author":"F D\u00edaz-Castro","year":"2024","unstructured":"D\u00edaz-Castro, F., Morselli, E. & Claret, M. Interplay between the brain and adipose tissue: a metabolic conversation. EMBO Rep. 25, 5293\u20135293 (2024).","journal-title":"EMBO Rep."},{"key":"1781_CR99","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.cmet.2022.08.004","volume":"34","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Extracellular vesicles mediate the communication of adipose tissue with brain and promote cognitive impairment associated with insulin resistance. Cell Metab. 34, 1264\u20131279.e8 (2022).","journal-title":"Cell Metab."},{"key":"1781_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1409000","volume":"15","author":"Y Han","year":"2024","unstructured":"Han, Y., Ye, S. & Liu, B. Roles of extracellular vesicles derived from healthy and obese adipose tissue in inter-organ crosstalk and potential clinical implication. Front. Endocrinol. 15, 1409000 (2024).","journal-title":"Front. Endocrinol."},{"key":"1781_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03409-1","volume":"14","author":"L Zhong","year":"2023","unstructured":"Zhong, L. et al. Neural stem cell-derived exosomes and regeneration: cell-free therapeutic strategies for traumatic brain injury. Stem Cell Res. Ther. 14, 198 (2023).","journal-title":"Stem Cell Res. Ther."},{"key":"1781_CR102","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0014-4886(03)00037-2","volume":"181","author":"P Lu","year":"2003","unstructured":"Lu, P., Jones, L., Snyder, E. & Tuszynski, M. Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury. Exp. Neurol. 181, 115\u2013129 (2003).","journal-title":"Exp. Neurol."},{"key":"1781_CR103","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ebiom.2018.11.026","volume":"38","author":"AD Vogel","year":"2018","unstructured":"Vogel, A. D., Upadhya, R. & Shetty, A. K. Neural stem cell derived extracellular vesicles: attributes and prospects for treating neurodegenerative disorders. EBioMedicine 38, 273\u2013282 (2018).","journal-title":"EBioMedicine"},{"key":"1781_CR104","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.celrep.2018.03.037","volume":"23","author":"MC Morton","year":"2018","unstructured":"Morton, M. C., Neckles, V. N., Seluzicki, C. M., Holmberg, J. C. & Feliciano, D. M. Neonatal subventricular zone neural stem cells release extracellular vesicles that act as a microglial morphogen. Cell Rep. 23, 78\u201389 (2018).","journal-title":"Cell Rep."},{"key":"1781_CR105","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s12975-017-0599-2","volume":"9","author":"RL Webb","year":"2018","unstructured":"Webb, R. L. et al. Human neural stem cell extracellular vesicles improve tissue and functional recovery in the murine thromboembolic stroke model. Transl. Stroke Res. 9, 530\u2013539 (2018).","journal-title":"Transl. Stroke Res."},{"key":"1781_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1200445","volume":"15","author":"S Attaluri","year":"2023","unstructured":"Attaluri, S. et al. Intranasally administered extracellular vesicles from human induced pluripotent stem cell-derived neural stem cells quickly incorporate into neurons and microglia in 5xFAD mice. Front. Aging Neurosci. 15, 1200445 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"1781_CR107","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2020.1809064","volume":"9","author":"R Upadhya","year":"2020","unstructured":"Upadhya, R. et al. Extracellular vesicles from human iPSC-derived neural stem cells: miRNA and protein signatures, and anti-inflammatory and neurogenic properties. J. Extracell. Vesicles 9, 1809064 (2020).","journal-title":"J. Extracell. Vesicles"},{"key":"1781_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21238994","author":"M Spinelli","year":"2020","unstructured":"Spinelli, M. et al. Neural stem cell-derived exosomes revert HFD-dependent memory impairment via CREB-BDNF signalling. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21238994 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1781_CR109","doi-asserted-by":"publisher","first-page":"18327","DOI":"10.1021\/acsnano.1c07587","volume":"15","author":"K Wang","year":"2021","unstructured":"Wang, K., Kumar, U. S., Sadeghipour, N., Massoud, T. F. & Paulmurugan, R. A Microfluidics-based scalable approach to generate extracellular vesicles with enhanced therapeutic microRNA loading for intranasal delivery to mouse glioblastomas. ACS Nano 15, 18327\u201318346 (2021).","journal-title":"ACS Nano"},{"key":"1781_CR110","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/17425247.2018.1378642","volume":"15","author":"G Li","year":"2018","unstructured":"Li, G., Bonamici, N., Dey, M., Lesniak, M. S. & Balyasnikova, I. V. Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies. Expert Opin. Drug Deliv. 15, 163\u2013172 (2018).","journal-title":"Expert Opin. Drug Deliv."},{"key":"1781_CR111","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/stem.3456","volume":"39","author":"S Herman","year":"2021","unstructured":"Herman, S., Fishel, I. & Offen, D. Intranasal delivery of mesenchymal stem cells-derived extracellular vesicles for the treatment of neurological diseases. Stem Cells 39, 1589\u20131600 (2021).","journal-title":"Stem Cells"},{"key":"1781_CR112","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ejcb.2009.02.001","volume":"88","author":"L Danielyan","year":"2009","unstructured":"Danielyan, L. et al. Intranasal delivery of cells to the brain. Eur. J. Cell Biol. 88, 315\u2013324 (2009).","journal-title":"Eur. J. Cell Biol."},{"key":"1781_CR113","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3727\/096368914X684970","volume":"23","author":"L Danielyan","year":"2014","unstructured":"Danielyan, L. et al. Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer\u2019s and Parkinson\u2019s disease. Cell Transplant. 23, 123\u2013139 (2014).","journal-title":"Cell Transplant."},{"key":"1781_CR114","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/rej.2010.1130","volume":"14","author":"L Danielyan","year":"2011","unstructured":"Danielyan, L. et al. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res. 14, 3\u201316 (2011).","journal-title":"Rejuvenation Res."},{"key":"1781_CR115","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3727\/096368912X657251","volume":"22","author":"N Wei","year":"2013","unstructured":"Wei, N. et al. Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice. Cell Transplant. 22, 977\u2013991 (2013).","journal-title":"Cell Transplant."},{"key":"1781_CR116","doi-asserted-by":"publisher","first-page":"14638","DOI":"10.1073\/pnas.0803670105","volume":"105","author":"H Ohtaki","year":"2008","unstructured":"Ohtaki, H. et al. Stem\/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory\/immune responses. Proc. Natl Acad. Sci. 105, 14638\u201314643 (2008).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1781_CR117","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.2174\/1389201021666201218130947","volume":"22","author":"P Dali","year":"2021","unstructured":"Dali, P. & Shende, P. Advances in stem cell therapy for brain diseases via the intranasal route. Curr. Pharm. Biotechnol. 22, 1466\u20131481 (2021).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"1781_CR118","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S350586","volume":"18","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. Optimization of an intranasal route for the delivery of human neural stem cells to treat a neonatal hypoxic-ischemic brain injury rat model. Neuropsychiatr. Dis. Treat. 18, 413 (2022).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"1781_CR119","doi-asserted-by":"publisher","first-page":"866","DOI":"10.5966\/sctm.2012-0045","volume":"1","author":"M Reitz","year":"2012","unstructured":"Reitz, M. et al. Intranasal delivery of neural stem\/progenitor cells: a noninvasive passage to target intracerebral glioma. Stem Cells Transl. Med. 1, 866\u2013873 (2012).","journal-title":"Stem Cells Transl. Med."},{"key":"1781_CR120","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.stemcr.2016.07.024","volume":"7","author":"M Dey","year":"2016","unstructured":"Dey, M. et al. Intranasal oncolytic virotherapy with CXCR4-enhanced stem cells extends survival in mouse model of glioma. Stem Cell Rep. 7, 471\u2013482 (2016).","journal-title":"Stem Cell Rep."},{"key":"1781_CR121","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/cgt.2009.80","volume":"17","author":"S Ito","year":"2010","unstructured":"Ito, S. et al. Human neural stem cells transduced with IFN-\u03b2 and cytosine deaminase genes intensify bystander effect in experimental glioma. Cancer Gene Ther. 17, 299\u2013306 (2010).","journal-title":"Cancer Gene Ther."},{"key":"1781_CR122","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12015-010-9154-1","volume":"7","author":"SU Kim","year":"2011","unstructured":"Kim, S. U. Neural stem cell-based gene therapy for brain tumors. Stem Cell Rev. Rep. 7, 130\u2013140 (2011).","journal-title":"Stem Cell Rev. Rep."},{"key":"1781_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-023-00384-8","volume":"12","author":"H Mo","year":"2023","unstructured":"Mo, H. et al. Intranasal administration of induced pluripotent stem cell-derived cortical neural stem cell-secretome as a treatment option for Alzheimer\u2019s disease. Transl. Neurodegener. 12, 50 (2023).","journal-title":"Transl. Neurodegener."},{"key":"1781_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29967-6","volume":"8","author":"M Meyer-Hermann","year":"2018","unstructured":"Meyer-Hermann, M. Estimation of the cancer risk induced by therapies targeting stem cell replication and treatment recommendations. Sci. Rep. 8, 11776 (2018).","journal-title":"Sci. Rep."},{"key":"1781_CR125","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.stem.2023.09.008","volume":"30","author":"LLM Derks","year":"2023","unstructured":"Derks, L. L. M. & van Boxtel, R. Stem cell mutations, associated cancer risk, and consequences for regenerative medicine. Cell Stem Cell 30, 1421\u20131433 (2023).","journal-title":"Cell Stem Cell"},{"key":"1781_CR126","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-29","volume":"9","author":"CA Herberts","year":"2011","unstructured":"Herberts, C. A., Kwa, M. S. G. & Hermsen, H. P. H. Risk factors in the development of stem cell therapy. J. Transl. Med. 9, 29 (2011).","journal-title":"J. Transl. Med."},{"key":"1781_CR127","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s15010-007-6350-2","volume":"35","author":"L Gil","year":"2007","unstructured":"Gil, L., Styczynski, J. & Komarnicki, M. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Infection 35, 421\u2013427 (2007).","journal-title":"Infection"},{"key":"1781_CR128","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1021\/acscentsci.1c01293","volume":"8","author":"SE Guimond","year":"2022","unstructured":"Guimond, S. E. et al. Synthetic heparan sulfate mimetic pixatimod (PG545) potently inhibits SARS-CoV-2 by disrupting the spike\u2013ACE2 interaction. ACS Cent. Sci. 8, 527\u2013545 (2022).","journal-title":"ACS Cent. Sci."},{"key":"1781_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/e1002986","author":"R Milho","year":"2012","unstructured":"Milho, R., Frederico, B., Efstathiou, S. & Stevenson, P. G. A heparan-dependent herpesvirus targets the olfactory neuroepithelium for host entry. PLoS Pathog. https:\/\/doi.org\/10.1038\/e1002986 (2012).","journal-title":"PLoS Pathog."},{"key":"1781_CR130","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.trsl.2022.05.002","volume":"248","author":"AJ Gadenstaetter","year":"2022","unstructured":"Gadenstaetter, A. J., Schmutzler, L., Grimm, D. & Landegger, L. D. Intranasal application of adeno-associated viruses: a systematic review. Transl. Res. 248, 87\u2013110 (2022).","journal-title":"Transl. Res."},{"key":"1781_CR131","doi-asserted-by":"crossref","unstructured":"Almahmoud A, Parekh HS, Paterson BM, Tupally KR, Vegh V. Intranasal delivery of imaging agents to the brain. Theranostics. 14, 5022\u20135101 (2024).","DOI":"10.7150\/thno.98473"},{"key":"1781_CR132","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.tim.2021.09.005","volume":"30","author":"NL Meyer","year":"2022","unstructured":"Meyer, N. L. & Chapman, M. S. Adeno-associated virus (AAV) cell entry: structural insights. Trends Microbiol. 30, 432\u2013451 (2022).","journal-title":"Trends Microbiol."},{"key":"1781_CR133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076310","volume":"8","author":"DF Aschauer","year":"2013","unstructured":"Aschauer, D. F., Kreuz, S. & Rumpel, S. Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PloS ONE 8, e76310 (2013).","journal-title":"PloS ONE"},{"key":"1781_CR134","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1089\/hum.2016.087","volume":"27","author":"M Hocquemiller","year":"2016","unstructured":"Hocquemiller, M., Giersch, L., Audrain, M., Parker, S. & Cartier, N. Adeno-associated virus-based gene therapy for CNS diseases. Human Gene Therapy 27, 478\u2013496 (2016).","journal-title":"Human Gene Therapy"},{"key":"1781_CR135","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1089\/hum.2013.189","volume":"25","author":"MJ Castle","year":"2014","unstructured":"Castle, M. J., Gershenson, Z. T., Giles, A. R., Holzbaur, E. L. & Wolfe, J. H. Adeno-associated virus serotypes 1, 8, and 9 share conserved mechanisms for anterograde and retrograde axonal transport. Human Gene Therapy 25, 705\u2013720 (2014).","journal-title":"Human Gene Therapy"},{"key":"1781_CR136","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","volume":"127","author":"R Thorne","year":"2004","unstructured":"Thorne, R., Pronk, G., Padmanabhan, V. & Frey Ii, W. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481\u2013496 (2004).","journal-title":"Neuroscience"},{"key":"1781_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13041-020-00596-3","volume":"13","author":"B Qi","year":"2020","unstructured":"Qi, B. et al. Nasal delivery of a CRMP2-derived CBD3 adenovirus improves cognitive function and pathology in APP\/PS1 transgenic mice. Mol. Brain 13, 1\u201311 (2020).","journal-title":"Mol. Brain"},{"key":"1781_CR138","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14356","volume":"8","author":"F Liu","year":"2016","unstructured":"Liu, F. et al. Antidepressant effect of recombinant NT4-NAP\/AAV on social isolated mice through intranasal route. Oncotarget 8, 10103 (2016).","journal-title":"Oncotarget"},{"key":"1781_CR139","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ymgme.2012.02.006","volume":"106","author":"DA Wolf","year":"2012","unstructured":"Wolf, D. A. et al. Lysosomal enzyme can bypass the blood\u2013brain barrier and reach the CNS following intranasal administration. Mol. Genet. Metab. 106, 131\u2013134 (2012).","journal-title":"Mol. Genet. Metab."},{"key":"1781_CR140","volume":"24","author":"LR Belur","year":"2020","unstructured":"Belur, L. R. et al. Intravenous delivery for treatment of mucopolysaccharidosis type I: a comparison of AAV serotypes 9 and rh10. Mol. Genet. Metab. Rep. 24, 100604 (2020).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"1781_CR141","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050785","author":"SS Issa","year":"2023","unstructured":"Issa, S. S. & Shaimardanova, A.A. Various AAV serotypes and their applications in gene therapy: an overview. Cells https:\/\/doi.org\/10.3390\/cells12050785 (2023).","journal-title":"Cells"},{"key":"1781_CR142","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00061-18","volume":"3","author":"JS LeCureux","year":"2018","unstructured":"LeCureux, J. S. & Dean, G. A. Lactobacillus mucosal vaccine vectors: immune responses against bacterial and viral antigens. mSphere 3, e00061\u201318 (2018).","journal-title":"mSphere"},{"key":"1781_CR143","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1128\/AEM.00295-07","volume":"73","author":"LG Berm\u00fadez-Humar\u00e1n","year":"2007","unstructured":"Berm\u00fadez-Humar\u00e1n, L. G. et al. Effects of intranasal administration of a leptin-secreting Lactococcus lactis recombinant on food intake, body weight, and immune response of mice. Appl. Environ. Microbiol. 73, 5300\u20135307 (2007).","journal-title":"Appl. Environ. Microbiol."},{"key":"1781_CR144","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.cell.2025.01.017","volume":"188","author":"H Shen","year":"2025","unstructured":"Shen, H. Engineered commensals for targeted nose-to-brain drug delivery. Cell 188, 1545\u20131562.e16 (2025).","journal-title":"Cell"},{"key":"1781_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48661-y","volume":"15","author":"H Shen","year":"2024","unstructured":"Shen, H. et al. Prodrug-conjugated tumor-seeking commensals for targeted cancer therapy. Nat. Commun. 15, 4343 (2024).","journal-title":"Nat. Commun."},{"key":"1781_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s43705-022-00205-5","volume":"3","author":"S van Kasteren","year":"2023","unstructured":"van Kasteren, S. & Rozen, D. E. Using click chemistry to study microbial ecology and evolution. ISME Commun. 3, 9 (2023).","journal-title":"ISME Commun."},{"key":"1781_CR147","doi-asserted-by":"publisher","DOI":"10.1002\/ijch.202200064","author":"Q Zheng","year":"2023","unstructured":"Zheng, Q. & Chang, P. V. Shedding light on bacterial physiology with click chemistry. Isr. J. Chem. https:\/\/doi.org\/10.1002\/ijch.202200064 (2023).","journal-title":"Isr. J. Chem."},{"key":"1781_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114364","volume":"187","author":"H Shen","year":"2022","unstructured":"Shen, H. et al. Engineered microbial systems for advanced drug delivery. Adv. Drug Deliv. Rev. 187, 114364 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1781_CR149","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41579-023-00875-5","volume":"21","author":"M Toyofuku","year":"2023","unstructured":"Toyofuku, M., Schild, S., Kaparakis-Liaskos, M. & Eberl, L. Composition and functions of bacterial membrane vesicles. Nat. Rev. Microbiol. 21, 415\u2013430 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"1781_CR150","doi-asserted-by":"publisher","first-page":"761","DOI":"10.7150\/thno.85917","volume":"14","author":"K Zheng","year":"2024","unstructured":"Zheng, K. et al. Engineered bacterial outer membrane vesicles: a versatile bacteria-based weapon against gastrointestinal tumors. Theranostics 14, 761\u2013787 (2024).","journal-title":"Theranostics"},{"key":"1781_CR151","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1021\/acsnano.4c13069","volume":"19","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Engineered therapeutic bacteria with high-yield membrane vesicle production inspired by eukaryotic membrane curvature for treating inflammatory bowel disease. ACS Nano 19, 2405\u20132418 (2025).","journal-title":"ACS Nano"},{"key":"1781_CR152","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","volume":"3","author":"PG Djupesland","year":"2013","unstructured":"Djupesland, P. G. Nasal drug delivery devices: characteristics and performance in a clinical perspective \u2014 a review. Drug Deliv. Transl. Res. 3, 42\u201362 (2013).","journal-title":"Drug Deliv. Transl. Res."},{"key":"1781_CR153","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","volume":"87","author":"L Illum","year":"2003","unstructured":"Illum, L. Nasal drug delivery \u2014 possibilities, problems and solutions. J. Controlled Release 87, 187\u2013198 (2003).","journal-title":"J. Controlled Release"},{"key":"1781_CR154","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1742-1241.1997.tb11466.x","volume":"51","author":"N Jones","year":"1997","unstructured":"Jones, N., Quraishi, S. & Mason, J. The nasal delivery of systemic drugs. Int J. Clin. Pract. 51, 308\u2013311 (1997).","journal-title":"Int J. Clin. Pract."},{"key":"1781_CR155","doi-asserted-by":"publisher","DOI":"10.3402\/jev.v4.26316","volume":"4","author":"OP Wiklander","year":"2015","unstructured":"Wiklander, O. P. et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J. Extracell. Vesicles 4, 26316 (2015).","journal-title":"J. Extracell. Vesicles"},{"key":"1781_CR156","doi-asserted-by":"crossref","unstructured":"Harkema, J. R., Plopper, C. G. & Pinkerton, K. E. Pulmonary Immunotoxicology.(Springer,2000). 1\u201359.","DOI":"10.1007\/978-1-4615-4535-4_1"},{"key":"1781_CR157","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/jps.21924","volume":"99","author":"SV Dhuria","year":"2010","unstructured":"Dhuria, S. V., Hanson, L. R. & Frey II, W. H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 99, 1654\u20131673 (2010).","journal-title":"J. Pharm. Sci."},{"key":"1781_CR158","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00373","volume":"11","author":"WM Pardridge","year":"2020","unstructured":"Pardridge, W. M. Blood-brain barrier and delivery of protein and gene therapeutics to brain. Front. Aging Neurosci. 11, 373 (2020).","journal-title":"Front. Aging Neurosci."},{"key":"1781_CR159","doi-asserted-by":"publisher","first-page":"9220","DOI":"10.1016\/j.biomaterials.2013.08.036","volume":"34","author":"T Kanazawa","year":"2013","unstructured":"Kanazawa, T., Akiyama, F., Kakizaki, S., Takashima, Y. & Seta, Y. Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. Biomaterials 34, 9220\u20139226 (2013).","journal-title":"Biomaterials"},{"key":"1781_CR160","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab105","volume":"3","author":"EJ Smith","year":"2021","unstructured":"Smith, E. J. et al. Use of high-content imaging to quantify transduction of AAV-PHP viruses in the brain following systemic delivery. Brain Commun. 3, fcab105 (2021).","journal-title":"Brain Commun."},{"key":"1781_CR161","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/10717544.2020.1748758","volume":"27","author":"W Meng","year":"2020","unstructured":"Meng, W. et al. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. Drug Deliv. 27, 585\u2013598 (2020).","journal-title":"Drug Deliv."},{"key":"1781_CR162","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","volume":"122","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi, F. & High, K. A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122, 23\u201336 (2013).","journal-title":"Blood"},{"key":"1781_CR163","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","volume":"101","author":"E Hudry","year":"2019","unstructured":"Hudry, E. & Vandenberghe, L. H. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101, 839\u2013862 (2019).","journal-title":"Neuron"},{"key":"1781_CR164","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.stem.2015.06.007","volume":"17","author":"A Trounson","year":"2015","unstructured":"Trounson, A. & McDonald, C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 17, 11\u201322 (2015).","journal-title":"Cell Stem Cell"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01781-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01781-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01781-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:03:09Z","timestamp":1788339789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01781-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":164,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1781"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01781-5","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}